Molecular imaging with SPECT as a tool for drug development
Abstract
Molecular imaging techniques are increasingly being used as valuable tools in the drug development process. Radionuclide-based imaging modalities such as single-photon emission computed tomography (SPECT) and positron emission tomography (PET) have proven to be useful in phases ranging from preclinical development to the initial stages of clinical testing. The high sensitivity of these imaging modalities makes them particularly suited for exploratory investigational new drug (IND) studies as they have the potential to characterize in vivo pharmacokinetics and biodistribution of the compounds using only a fraction of the intended therapeutic dose (microdosing). This information obtained at an early stage of clinical testing results in a better selection among promising drug candidates, thereby increasing the success rate of agents entering clinical trials and the overall efficiency of the process. In this article, we will review the potential applications of SPECT imaging in the drug development process with an emphasis on its applications in exploratory IND studies.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
By utilizing radiotracers labelled with radioisotopes, clinicians can accurately identify specific biomarkers and assess extent of disease progression through high-resolution imaging modalities such as PET and SPECT.
“By utilizing radiotracers labelled with radioisotopes, clinicians can accurately identify specific biomarkers and assess the extent of disease progression through high-resolution imaging modalities such as PET and SPECT [47].”
From Radiopharmaceuticals: navigating the frontier of precision medicine and therapeutic innovation (2024) · cites this paper as [47]
Cites
Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework
Biomarkers Definitions Working Group (2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.113989 · Cited by 6,771 · see citing works
The price of innovation: new estimates of drug development costs
DiMasi, J. A., Hansen, R. W., & Grabowski, H. G. (2003) · Journal of Health Economics · doi:10.1016/s0167-6296(02)00126-1 · Cited by 4,265 · see citing works
Can the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167 · see citing works
Tumorigenesis and the angiogenic switch
Bergers, G., & Benjamin, L. E. (2003) · Nature reviews. Cancer · doi:10.1038/nrc1093 · Cited by 3,559 · see citing works
Koopman, G., Reutelingsperger, C. P. M., Kuijten, G., Keehnen, R. M. J., Pals, S. T., & van Oers, M. H. J. (1994) · Blood · doi:10.1182/blood.v84.5.1415.1415 · Cited by 2,687 · see citing works
Koopman, G., Reutelingsperger, C., Kuijten, G., et al. (1994) · Blood · doi:10.1182/blood.v84.5.1415.bloodjournal8451415 · Cited by 2,068 · see citing works
Role of integrins in cell invasion and migration
Hood, J. D., & Cheresh, D. A. (2002) · Nature reviews. Cancer · doi:10.1038/nrc727 · Cited by 1,781 · see citing works
Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug
Capdeville, R., Buchdunger, E., Zimmermann, J., & Matter, A. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd839 · Cited by 1,391 · see citing works
Pardridge, W. M. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2006.10.013 · Cited by 1,191 · see citing works
Molecular imaging in drug development
Willmann, J. K., van Bruggen, N., Dinkelborg, L. M., & Gambhir, S. S. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2290 · Cited by 1,175 · see citing works
Johnson, J. I., Decker, S., Zaharevitz, D. W., Rubinstein, L., Venditti, J. M., Schepartz, S. A., Kalyandrug, S., Christian, M. C., Arbuck, S. G., Hollingshead, M. G., et al. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.1796 · Cited by 856 · see citing works
Molecular imaging in drug discovery and development
Rudin, M., & Weissleder, R. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1007 · Cited by 811 · see citing works
Lesko, L., & Atkinson, A. (2001) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.41.1.347 · Cited by 465 · see citing works
Risks in new drug development: Approval success rates for investigational drugs
DiMasi, J. A. (2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.115446 · Cited by 455 · see citing works
Haubner, R., Wester, H. J., Burkhart, F., Senekowitsch–Schmidtke, R., Weber, W., Goodman, S. L., Kessler, H., & Schwaiger, M. (2001) · PubMed · Cited by 381 · see citing works
Recent Advances in SPECT Imaging
Madsen, M. T. (2007) · Journal of Nuclear Medicine · doi:10.2967/jnumed.106.032680 · Cited by 339 · see citing works
Past, present, and future of annexin A5: from protein discovery to clinical applications.
Boersma, H. H., Kietselaer, B., Stolk, L. M., Bennaghmouch, A., Hofstra, L., Narula, J., Heidendal, G. A. K., & Reutelingsperger, C. P. M. (2005) · PubMed · Cited by 333 · see citing works
Imaging of Cell Proliferation: Status and Prospects
Bading, J. R., & Shields, A. F. (2008) · Journal of Nuclear Medicine · doi:10.2967/jnumed.107.046391 · Cited by 321 · see citing works
Radiotherapy with a Radiolabeled Somatostatin Analogue, [ 111 In‐DTPA‐ d ‐Phe 1 ]‐Octreotide
Krenning, E. P., Kooij, P. P. M., Bakker, W. H., Breeman, W. A., Postema, P. T., Kwekkeboom, D. J., Oei, H. Y., de Jong, M., Visser, T. J., Reijs, A. E. M., et al. (1994) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1994.tb17300.x · Cited by 313 · see citing works
Apoptosome dysfunction in human cancer
Hajra, K. M., & Liu, J. R. (2004) · APOPTOSIS · doi:10.1023/b:appt.0000045786.98031.1d · Cited by 290 · see citing works
Belhocine, T., Steinmetz, N. D., Hustinx, R., et al. (2002) · PubMed · Cited by 290 · see citing works
Molecular imaging of VEGF receptors in angiogenic vasculature with single-chain VEGF-based probes
Backer, M. V., Levashova, Z., Patel, V., Jehning, B. T., Claffey, K. P., Blankenberg, F. G., & Backer, J. M. (2007) · Nature Medicine · doi:10.1038/nm1522 · Cited by 242 · see citing works
MicroPET imaging of breast cancer ?-integrin expression with Cu-labeled dimeric RGD peptides
Chen, X., Liu, S., Hou, Y., Tohme, M., PARK, R., Bading, J. R., & Conti, P. (2004) · Molecular Imaging and Biology · doi:10.1016/j.mibio.2004.06.004 · Cited by 210 · see citing works
Kenanova, V. E., Olafsen, T., Crow, D. M., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.622.65.2 · Cited by 207 · see citing works
Apoptosis-detecting radioligands: current state of the art and future perspectives
Lahorte, C. M. M., Vanderheyden, J., Steinmetz, N., de Wiele, C. V., Dierckx, R., & Slegers, G. (2004) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-004-1555-4 · Cited by 195 · see citing works
Tumor Imaging and Therapy Using Radiolabeled Somatostatin Analogues
de Jong, M., Breeman, W. A. P., Kwekkeboom, D. J., et al. (2009) · Accounts of Chemical Research · doi:10.1021/ar800188e · Cited by 178 · see citing works
How molecular imaging is speeding up antiangiogenic drug development
Cai, W., Rao, J., Gambhir, S. S., & Chen, X. S. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0395 · Cited by 175 · see citing works
Comparison of a Monomeric and Dimeric Radiolabeled RGD-Peptide for Tumor Targeting
Janssen, M., Oyen, W. J. G., Massuger, L. F. A. G., et al. (2002) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/108497802320970244 · Cited by 174 · see citing works
The Role of Imaging in Proof of Concept for CNS Drug Discovery and Development
Wong, D. F., Tauscher, J. T., & Gründer, G. (2008) · Neuropsychopharmacology · doi:10.1038/npp.2008.166 · Cited by 167 · see citing works
Rationale for Biomarkers and Surrogate End Points in Mechanism-Driven Oncology Drug Development
Park, J. W., Kerbel, R. S., Kelloff, G. J., Barrett, J. C., Chabner, B. A., Parkinson, D. R., Peck, J. C., Ruddon, R. W., Sigman, C. C., & Slamon, D. J. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0785 · Cited by 158 · see citing works
Antibodies for Molecular Imaging of Cancer
Wu, A. M., & Olafsen, T. (2008) · The Cancer Journal · doi:10.1097/ppo.0b013e31817b07ae · Cited by 149 · see citing works
O’Connor, M. K., & KEMP, B. J. (2006) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2006.05.005 · Cited by 149 · see citing works
Liersch, T., Meller, J., Kulle, B., Behr, T. M., Markus, P. M., Langer, C., Ghadimi, Β. M., Wegener, W. A., Kovacs, J., Horak, I. D., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.18.622 · Cited by 134 · see citing works
Vaneycken, I., Govaert, J., Vincke, C., Caveliers, V., Lahoutte, T., BAETSELIER, P. D., Raes, G., Bossuyt, A. M., Muyldermans, S., & Devoogdt, N. (2010) · Journal of Nuclear Medicine · doi:10.2967/jnumed.109.069823 · Cited by 126 · see citing works
Integrin receptor imaging of breast cancer: a proof-of-concept study to evaluate 99mTc-NC100692.
Bach‐Gansmo, T., Danielsson, R., Saracco, A., et al. (2006) · PubMed · Cited by 119 · see citing works
Talbot, P. S. (2002) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(02)00099-8 · Cited by 119 · see citing works
[99mTc]HYNIC-RGD for imaging integrin αvβ3 expression
Decristoforo, C., Faintuch-Linkowski, B., Rey, A. M., et al. (2006) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2006.09.001 · Cited by 117 · see citing works
Peptide receptor therapies in neuroendocrine tumors
Bodei, L., Ferone, D., Grana, C. M., Cremonesi, M., Signore, A., Dierckx, R. A., & Paganelli, G. (2009) · Journal of Endocrinological Investigation · doi:10.1007/bf03345728 · Cited by 116 · see citing works
Phase 0 Clinical Trials: Conceptions and Misconceptions
Kummar, S., Rubinstein, L., Kinders, R. J., Parchment, R. E., Gutierrez, M. E., Murgo, A. J., Ji, J., Mroczkowski, B., Pickeral, O. K., Simpson, M., et al. (2008) · The Cancer Journal · doi:10.1097/ppo.0b013e318172d6f3 · Cited by 110 · see citing works
Kartachova, M. S., Haas, R. L., Olmos, R. A. V., et al. (2004) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2004.07.008 · Cited by 110 · see citing works
Cancer Imaging With Fluorine-18–Labeled Choline Derivatives
Kwee, S. A., DeGrado, T. R., Talbot, J., et al. (2007) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2007.07.003 · Cited by 106 · see citing works
Brooks, D. J. (2005) · NeuroRx · doi:10.1602/neurorx.2.2.226 · Cited by 106 · see citing works
Designing Phase 0 Cancer Clinical Trials
Murgo, A. J., Kummar, S., Rubinstein, L., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4560 · Cited by 105 · see citing works
Fischman, A. J., Alpert, N. M., & Rubin, R. H. (2002) · Clinical Pharmacokinetics · doi:10.2165/00003088-200241080-00003 · Cited by 102 · see citing works
Vascular endothelial growth factor‐targeted therapy in metastatic renal cell carcinoma
Rini, B. I. (2009) · Cancer · doi:10.1002/cncr.24227 · Cited by 85 · see citing works
Phase 0 Clinical Trials in Cancer Drug Development: From FDA Guidance to Clinical Practice
Kinders, R. J., Parchment, R. E., Ji, J. H., et al. (2007) · Molecular Interventions · doi:10.1124/mi.7.6.9 · Cited by 83 · see citing works
Garner, R. C., & Lappin, G. (2006) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2006.02575.x · Cited by 79 · see citing works
In vivo tumor angiogenesis imaging with site-specific labeled 99mTc-HYNIC-VEGF
Blankenberg, F. G., Backer, M. V., Levashova, Z. B., et al. (2006) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-006-0099-1 · Cited by 77 · see citing works
In vivo imaging of tumour angiogenesis in mice with the αvβ3 integrin-targeted tracer 99mTc-RAFT-RGD
Sancey, L., Ardisson, V., Riou, L. M., Ahmadi, M., Batlle, D. M., Boturyn, D., Dumy, P., Fagret, D., Ghezzi, C., & Vuillez, J.-P. (2007) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-007-0497-z · Cited by 66 · see citing works
DiFilippo, F. P. (2008) · Physics in Medicine and Biology · doi:10.1088/0031-9155/53/15/012 · Cited by 66 · see citing works
Akabani, G., Cokgor, I., Coleman, R. E., Trotter, D. E. G., Wong, T. Z., Friedman, H. S., Friedman, A. H., Garcia-Turner, A. M., Herndon, J. E., DeLong, D. M., et al. (2000) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(99)00500-3 · Cited by 65 · see citing works
Fani, M., Psimadas, D., Zikos, C. C., et al. (2006) · PubMed · Cited by 56 · see citing works
Rodrigues, M., Traub‐Weidinger, T., Li, S., et al. (2006) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-005-0020-3 · Cited by 49 · see citing works
Noninvasive structural, functional, and molecular imaging in drug development
Rudin, M. (2009) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2009.03.025 · Cited by 49 · see citing works
Peintinger, F., Buzdar, A. U., Kuerer, H. M., et al. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn427 · Cited by 49 · see citing works
Kuwert, T., Probst‐Cousin, S., Woesler, B., et al. (1997) · PubMed · Cited by 48 · see citing works
Chrastina, A., Valadon, P., Massey, K. A., et al. (2010) · Journal of Vascular Research · doi:10.1159/000313880 · Cited by 47 · see citing works
Dort, M. V., Rehemtulla, A., & Ross, B. D. (2008) · Current Computer - Aided Drug Design · doi:10.2174/157340908783769265 · Cited by 47 · see citing works
Rudin, M. (2007) · European Radiology · doi:10.1007/s00330-007-0619-9 · Cited by 46 · see citing works
Synthesis and biological evaluation of potent αvβ3-integrin receptor antagonists
Dijkgraaf, I., Kruijtzer, J. A. W., Frielink, C., et al. (2006) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2006.08.008 · Cited by 44 · see citing works
Yang, J., Guo, H., Gallazzi, F., et al. (2009) · Bioconjugate Chemistry · doi:10.1021/bc9001954 · Cited by 41 · see citing works
Dort, M. E. V., Lee, K. C., Hamilton, C. A., et al. (2008) · Molecular Imaging · doi:10.2310/7290.2008.00020 · Cited by 33 · see citing works
Jager, P. L., Plaat, B. E. C., de Vries, E. G. E., et al. (2000) · PubMed · Cited by 31 · see citing works
Eberlé, A. N., & Froidevaux, S. (2003) · Journal of Molecular Recognition · doi:10.1002/jmr.633 · Cited by 28 · see citing works
Kartachova, M. S., Olmos, R. A. V., Haas, R. L., et al. (2006) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-006-0070-1 · Cited by 28 · see citing works
Imaging biomarkers as surrogate endpoints for drug development
Richter, W. S. (2006) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-006-0129-z · Cited by 28 · see citing works
Tumour angiogenesis pathways: related clinical issues and implications for nuclear medicine imaging
de Wiele, C. V., Oltenfreiter, R., Winter, O. D., Signore, A., Slegers, G., & Dierckx, R. A. J. O. (2002) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-002-0783-8 · Cited by 28 · see citing works
Defective Apoptosis Underlies Chemoresistance in Ovarian Cancer
Hajra, K. M., Tan, L., & Liu, J. R. (2008) · Springer eBooks · doi:10.1007/978-0-387-68969-2_16 · Cited by 22 · see citing works
Microdosing, Imaging Biomarkers and SPECT: A Multi-Sided Tripod to Accelerate Drug Development
Pauwels, E. K. J., Bergström, K., Mariani, G., et al. (2009) · Current Pharmaceutical Design · doi:10.2174/138161209787582039 · Cited by 21 · see citing works
Self-citationKageyama, H., Morita, K., Katoh, C., et al. (2005) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-005-1863-3 · Cited by 19 · see citing works
Imaging biomarkers: from research to patient care—a shift in view
Lucignani, G. (2007) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-007-0569-0 · Cited by 12 · see citing works
Cheung, M. C., MacEachern, J., Haynes, A. E., Meyer, R. M., & Imrie, K. (2009) · Current Oncology · doi:10.3747/co.v16i5.385 · Cited by 12 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Radiopharmaceuticals: navigating the frontier of precision medicine and therapeutic innovation
Dhoundiyal, S., Srivastava, S., Kumar, S., Singh, G., Ashique, S., Pal, R., Mishra, N., & Taghizadeh-Hesary, F. (2024) · European Journal of Medical Research · doi:10.1186/s40001-023-01627-0 · Cited by 144 · see citing works
“By utilizing radiotracers labelled with radioisotopes, clinicians can accurately identify specific biomarkers and assess the extent of disease progression through high-resolution imaging modalities such as PET and SPECT [47].”
Background
- Authors
- Gomes, C. M., Abrunhosa, A. J., Ramos, P., & Pauwels, E. K. J.
- Affiliations
- University of Coimbra (PT)
- Leiden University Medical Center (NL)
- Corresponding author
- Gomes, Célia M.
- Venue
- Advanced Drug Delivery Reviews
- Publisher
- Elsevier BV
- Published
- 2011-06
- Volume
- 63
- Issue
- 7
- Pages
- 547-554
- ISSN
- 0169-409X (ISSN-L)
- OpenAlex
- W2063379502
- Cited by
- 100
- References
- 72
- Citations by year
- 2025: 3 · 2024: 5 · 2023: 7 · 2022: 4 · 2021: 11 · 2020: 5 · 2019: 9 · 2018: 9 · 2017: 10 · 2016: 6 · 2015: 4 · 2014: 11 · 2013: 7 · 2012: 6
- FWCI
- 0.73
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Advanced Drug Delivery Reviews (publishedVersion)
- PubMed (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Leiden Repository (Leiden University) (submittedVersion)
- Topics
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Keywords
- molecular imaging, single photon emission computed tomography, drug development, in vivo pharmacokinetics, tissue distribution, microdosing, scintigraphy, preclinical drug testing
- MeSH terms
- Animals, Clinical Trials as Topic, Dose-Response Relationship, Drug, Drug Evaluation, Preclinical, Humans, Tissue Distribution, Drug Design, Drugs, Investigational, Tomography, Emission-Computed, Single-Photon, Positron-Emission Tomography
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
